209P Trastuzumab plus lapatinib or chemotherapy in patients with HER2-positive advanced breast cancer refractory to anti-HER2 therapies: A randomized, multicenter, phase II trial (GIM12-TYPHER)
| Autor: | De Angelis, C., Pagliuca, M., Gamucci, T., Mansutti, M., Ballatore, Z., De Laurentiis, M., Bordonaro, R., Pazzola, A., Leonardi, V., Bruzzese, D., Mosconi, A.M., Molica, C., Cinieri, S., Fabi, A., Del Mastro, L., Puglisi, F., de Placido, S., Giuliano, M., Arpino, G. |
|---|---|
| Zdroj: | In ESMO Open May 2023 8(1) Supplement 4 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|